Artificial intelligence is changing how scientists discover potential medicines by helping them predict which molecules might treat a disease, how those molecules could interact with biological targets, and which candidates deserve laboratory testing. Instead of relying entirely on time-consuming experiments and traditional screening methods, researchers can use AI to analyze large biological datasets, generate new molecular structures, and prioritize compounds with promising properties.
But predicting a promising drug is not the same as discovering a medicine that works. AI models operate on data and mathematical representations of biology, while actual drug development depends on physical interactions inside cells, tissues, organs, and ultimately the human body. Laboratory experiments are therefore essential for determining whether computational predictions reflect biological reality.
The most effective approach combines AI with experimental science. Algorithms narrow the search, researchers evaluate the predictions, and laboratory tests provide evidence that guides the next round of discovery. This cycle connects molecular prediction to measurable biological effects, turning computational ideas into candidates that may eventually become medicines.
Why drug discovery is difficult
Developing a medicine begins with understanding a disease and identifying a biological process that can be altered to treat it. That process might involve a protein that drives inflammation, an enzyme that supports the growth of cancer cells, or a viral protein required for infection.
Scientists first identify a potential therapeutic target, such as a protein, and investigate whether changing its activity could improve the disease. They then search for a molecule that interacts with the target in a useful way without causing unacceptable harm.
This search is difficult because biological systems are complex. A molecule may bind tightly to a protein but fail to change its activity. It may work in isolated cells but break down too quickly in the body. It may reach the intended tissue yet affect other proteins, producing unwanted side effects.
Drug candidates must also meet practical chemical requirements. They need suitable stability, solubility, absorption, distribution, and elimination properties. These characteristics influence whether a compound can reach its target at an effective concentration and remain there long enough to produce a therapeutic effect.
Traditional drug discovery uses methods such as biochemical experiments, cell-based assays, and high-throughput screening, which tests many compounds automatically. These methods remain fundamental, but they can consume substantial time and resources. The number of possible drug-like molecules is enormous, making it impossible to test every candidate experimentally.
AI helps address this search problem by estimating which possibilities are most worth investigating. Its purpose is not to eliminate experimentation but to direct experimental effort toward better-informed choices.
How AI learns to predict molecular behavior
AI drug discovery uses computational models to identify patterns in chemical, biological, and experimental data. Different models solve different problems, and their usefulness depends on the quality of their training data, the question being asked, and how closely the model’s predictions match the conditions of real experiments.
Many systems use machine learning, a branch of AI in which algorithms learn statistical relationships from examples rather than relying exclusively on explicitly programmed rules. A model might learn how molecular structure relates to a compound’s ability to bind a protein, inhibit an enzyme, or remain stable under particular conditions.
To process these relationships, researchers represent molecules in forms that computers can analyze. A molecule can be described through its atoms, chemical bonds, molecular fingerprints, three-dimensional structure, or a combination of these features. Biological targets can also be represented using information about their amino acid sequences, structures, and known interactions.
During training, a model examines examples with known outcomes. For instance, it may receive the structures of compounds alongside experimental measurements of how strongly they bind to a particular protein. It then learns patterns associated with stronger or weaker binding and uses those patterns to estimate the properties of new compounds.
The output is a prediction, not a direct measurement. A model that predicts strong binding does not establish that binding will occur in a laboratory, and a model that performs well on familiar molecules may struggle with unfamiliar chemical structures.
This distinction matters because AI performance depends heavily on the data available to it. Experimental datasets may contain inconsistent measurements, incomplete records, or many examples of one type of molecule and very few of another. Models can also learn misleading correlations that happen to occur in the training data without reflecting the underlying biology.
Researchers therefore evaluate models using compounds or datasets that were not used during training. They also examine uncertainty, test performance across different chemical structures, and compare predictions with appropriate experimental results. Reliable drug discovery requires knowing not only what a model predicts but also when its predictions are likely to be wrong.
Finding biological targets and predicting molecular interactions
AI can contribute to drug discovery before researchers select a candidate molecule. By analyzing biological datasets, it can help identify proteins, genes, and pathways associated with disease.
For example, machine learning can examine patterns in gene activity, protein measurements, or genetic data to identify biological processes that differ between diseased and healthy tissues. These patterns may suggest a possible therapeutic target. However, an association does not prove that a biological factor causes the disease or that changing it will improve the condition. Researchers must investigate the proposed target experimentally.
Once a target has been selected, AI can help predict how a molecule might interact with it. One important task is estimating whether a compound will bind to a target protein and, where possible, how that interaction might occur.
Proteins are made of amino acids and fold into three-dimensional structures. Their shapes, electrical properties, flexibility, and chemical environments influence which molecules can interact with them. A small molecule may fit into a pocket on a protein’s surface, forming interactions that alter the protein’s activity.
AI models can use protein sequences, predicted structures, known binding data, and chemical information to estimate these interactions. Structural prediction systems can help researchers understand a protein’s likely shape, while molecular interaction models can evaluate possible binding arrangements or estimate binding-related properties.
Protein structure prediction and drug-binding prediction are related but distinct tasks. Predicting a protein’s structure does not automatically reveal which compound will bind to it, whether that compound will change its function, or whether the interaction will be therapeutically useful.
Protein structures are also dynamic. They can adopt different shapes, interact with other molecules, and behave differently depending on their environment. A predicted structure may omit important features or fail to capture the form of the protein that a drug encounters under experimental conditions.
Computational tools can narrow the search and suggest testable hypotheses, but laboratory measurements are needed to establish whether the proposed interaction actually occurs.
Generating and selecting promising drug candidates
After identifying a target, researchers need molecules that can interact with it and produce a useful biological effect. AI can help search existing chemical libraries, improve known compounds, or generate entirely new molecular structures.
In conventional virtual screening, a computer evaluates a collection of existing molecules and ranks them according to predicted properties. Depending on the method, those properties might include compatibility with a target, likelihood of binding, chemical similarity to known active compounds, or predicted toxicity.
This approach can reduce the number of compounds that require experimental testing. Instead of testing every molecule in a large collection, scientists can prioritize a smaller group that combines promising predictions with chemical diversity and practical feasibility.
Generative AI takes a different approach. Rather than simply ranking existing molecules, it produces candidate structures based on learned chemical patterns and specified design objectives. Researchers may ask a model to propose molecules with particular structural features, predicted activity against a target, or improved properties relative to an existing compound.
A generated molecule must still satisfy the rules of chemistry. Its atoms must form chemically plausible bonds, and the resulting structure must be stable enough to synthesize and study. Even a chemically valid structure may be difficult or expensive to manufacture, poorly soluble, unstable, or biologically inactive.
Drug design also involves competing objectives. A compound that binds strongly to its target may have poor solubility. A molecule that enters cells efficiently may interact with unintended proteins. Improving one property can worsen another, so researchers generally seek a balance rather than a single maximum score.
AI can help compare these trade-offs, but its rankings are only as reliable as the underlying models and data. A compound with an excellent predicted score may perform poorly in the laboratory, while a less highly ranked compound may reveal an unexpected and valuable interaction.
The practical goal is to select a manageable set of candidates with complementary strengths, then test them to determine which predictions hold up.
From computer predictions to physical molecules
Before a proposed drug candidate can be tested biologically, researchers usually need to obtain the actual compound. That may involve purchasing it from a chemical supplier, retrieving it from an existing collection, or synthesizing it in a laboratory.
Chemical synthesis converts starting materials into a desired molecular structure through a sequence of reactions. AI tools can assist with planning these reactions by suggesting possible routes from available starting materials to the target molecule. Other computational methods help estimate reaction outcomes or identify conditions worth investigating.
However, a proposed synthesis route is not a guarantee of success. Reactions may produce unwanted byproducts, yield less material than expected, or fail under the suggested conditions. Chemists must evaluate whether the route is practical, reproducible, safe, and compatible with the required scale.
Once a compound has been prepared, its identity and purity must be verified. Analytical techniques such as mass spectrometry and nuclear magnetic resonance spectroscopy help establish whether the material has the expected chemical characteristics and whether impurities are present.
These checks are essential to interpreting biological experiments. If a compound appears inactive, researchers need confidence that they tested the intended molecule. If it appears active, they must consider whether an impurity or another experimental factor could explain the result.
This is the point at which a computational candidate becomes a physical substance whose properties can be measured directly. The transition is important because no prediction can substitute for confirming that the intended molecule exists and is suitable for testing.
How laboratory testing validates AI predictions
Laboratory testing determines whether an AI-designed or AI-selected molecule behaves as expected under controlled experimental conditions. Researchers typically progress from relatively focused measurements toward increasingly complex biological systems, although the exact sequence depends on the target, disease, and type of drug.
Biochemical and cell-based assays
An early experiment may test whether a compound binds to a purified protein or changes its activity in a biochemical assay. Researchers measure outcomes such as binding strength, enzyme activity, or the degree to which the compound inhibits a target’s function.
A useful measure is the half-maximal inhibitory concentration, commonly called IC50. Under specified experimental conditions, this is the concentration of a compound that reduces a measured activity by half. A lower IC50 can indicate greater inhibitory potency in that assay, but the value depends on the experimental setup and does not by itself establish how well a drug will work in a person.
Researchers may also measure the half-maximal effective concentration, or EC50, when evaluating the concentration associated with half of a compound’s maximum observed effect. IC50 and EC50 describe different experimental outcomes and should not be treated as interchangeable measures of drug performance.
A molecule that performs well in a purified-protein assay must next be evaluated in a more biologically complex setting when appropriate. Cell-based assays reveal whether the compound can reach its target inside cells and produce the intended response. They can also help detect early signs of cellular toxicity.
For example, suppose an AI model identifies a small molecule predicted to inhibit a protein involved in cancer cell growth. A biochemical assay might confirm that the molecule inhibits the protein’s activity. A cell-based experiment would then investigate whether the compound enters the relevant cells, changes the expected signaling pathway, and affects cell growth at concentrations that do not cause indiscriminate cellular damage.
These results answer different questions. Direct inhibition of a purified protein supports the proposed molecular interaction. A corresponding effect in cells provides evidence that the mechanism may operate in a biological environment. Neither result alone proves that the compound will treat cancer safely or effectively in patients.
Researchers use controls, repeated measurements, and concentration-response experiments to distinguish genuine activity from experimental noise. They may also compare the candidate with known active compounds and inactive controls. When results contradict the model’s predictions, the discrepancy becomes useful information rather than merely a failed experiment.
A compound that shows no activity may indicate that the predicted interaction was incorrect, that the molecule could not reach the target, or that the experimental conditions did not capture the relevant mechanism. Determining which explanation is most likely helps scientists decide whether to redesign the molecule, revise the model, or abandon the candidate.
The feedback loop between AI and the laboratory
AI-driven drug discovery works best as an iterative process rather than a one-way sequence from computer to laboratory. Each round of testing produces evidence that can improve the next round of predictions.
Suppose researchers test a group of AI-selected compounds against a protein. Some show strong activity, others show weak activity, and many show none. These results provide information about which chemical features are associated with the observed behavior.
Scientists can use the new measurements to update a predictive model, retrain it, or adjust the criteria used to select candidates. The revised model then helps prioritize another group of compounds for synthesis and testing.
This process is related to active learning, a strategy in which a model helps identify which additional data would be most useful to collect. Rather than selecting compounds solely because they have the highest predicted activity, researchers may also test molecules that could clarify an uncertain prediction or explore a poorly represented region of chemical space.
Chemical space refers to the vast range of possible molecular structures. Exploring it strategically is important because training data rarely cover every type of molecule a model may encounter.
The feedback loop also helps expose systematic errors. If a model consistently predicts strong activity for compounds that fail in cell-based experiments, researchers can investigate whether it is overlooking cell permeability, compound stability, or other properties that influence biological performance.
Experimental results do not automatically improve a model. Measurements must be sufficiently reliable, labeled correctly, and collected under conditions that allow meaningful comparison. Differences between laboratories or assay methods can complicate interpretation, so researchers need careful data management and experimental design.
When computational predictions and experimental evidence inform one another, the discovery process becomes more adaptive. AI suggests what to test, experiments reveal what happens, and the resulting evidence guides the next decision.
Why promising molecules often fail
One of the most important facts about AI drug discovery is that success at one stage does not guarantee success at the next. A compound may bind its intended target yet fail to produce the desired effect in cells. It may work in cells but fail in animals because it is rapidly broken down or cannot reach the relevant tissue.
A molecule may also interact with unintended proteins. These off-target effects can reduce its usefulness or produce harmful biological responses. Computational models can estimate some risks, but predicting all relevant interactions across the human body remains difficult.
Pharmacokinetics describes what the body does to a drug: how it is absorbed, distributed, metabolized, and eliminated. Pharmacodynamics describes what the drug does to the body, including its biological effects and the relationship between exposure and response.
These properties help determine whether a candidate can reach the right place at the right concentration for an appropriate period. A compound with strong activity in a laboratory assay may be unsuitable if the body clears it too quickly, if it cannot be administered effectively, or if the required dose would be toxic.
Researchers therefore investigate properties such as solubility, chemical stability, membrane permeability, metabolic behavior, and potential toxicity. They may also use animal studies when scientifically justified to evaluate exposure, effects in a living organism, and safety questions that simpler systems cannot answer adequately.
AI can help prioritize these investigations, identify patterns in existing safety data, and predict some undesirable properties. However, these predictions have limitations, particularly when a candidate differs substantially from compounds represented in the training data or when toxicity depends on complex interactions among organs and biological pathways.
The development process also includes questions that molecular prediction alone cannot resolve. A treatment must be manufacturable, sufficiently stable, deliverable to patients, and supported by evidence of acceptable safety and clinical benefit. These requirements extend well beyond the accuracy of any single AI model.
From laboratory validation to human testing
Compounds that survive early laboratory studies may progress through additional preclinical research, including studies of how they behave in living systems and whether their potential benefits justify further development.
Before a new drug is tested in people in the United States, its developers generally must submit an investigational new drug application to the Food and Drug Administration, unless an applicable exemption applies. The supporting evidence is intended to help establish that proposed clinical testing can proceed with appropriate protections for participants.
Clinical trials then evaluate the candidate in humans. Early studies examine safety, tolerability, and how the body handles the drug. Later studies investigate whether the treatment provides meaningful benefits for the intended condition, how it compares with relevant alternatives, and which risks may accompany its use.
AI can assist with parts of this process, including analyzing clinical data, identifying potential patient subgroups, and supporting the design or interpretation of studies. But a model’s predictions cannot establish clinical efficacy. That requires evidence from appropriately designed human studies.
A drug may fail in clinical development even when its molecular mechanism is scientifically credible. The target may not play the expected role in human disease, the treatment effect may be too small, or adverse effects may outweigh the benefits. Differences between laboratory models and human biology are a persistent challenge in medicine, regardless of whether AI was used to identify the candidate.
For this reason, the success of AI in drug discovery should not be measured only by how many molecules it generates or how accurately it predicts binding. More meaningful measures include whether it helps researchers identify experimentally confirmed compounds, improve the quality of candidates entering development, reduce unnecessary testing, or make difficult therapeutic targets more accessible to investigation.
What AI can realistically contribute to medicine
AI offers drug discovery a way to search complex chemical and biological possibilities more systematically. It can help scientists prioritize compounds, predict selected molecular properties, generate candidate structures, plan chemical synthesis, and learn from experimental results. These capabilities are particularly valuable when they help researchers focus limited laboratory resources on questions with the greatest scientific value.
Its limitations are equally important. Models inherit weaknesses from their training data, can fail when applied to unfamiliar molecules, and may overlook biological factors that are difficult to represent computationally. A plausible prediction can be wrong even when the model is technically sophisticated.
The central scientific challenge is therefore not simply to create better predictions. It is to establish which predictions are reliable enough to guide experiments, determine why others fail, and use the resulting evidence to improve subsequent decisions.
AI does not remove the need for medicinal chemists, biologists, pharmacologists, toxicologists, or clinical researchers. It changes how they can investigate a problem and how efficiently they may move through possible solutions. Laboratory testing remains the essential bridge between what a computer predicts about a molecule and what that molecule actually does.
The promise of AI in drug discovery lies in that connection: computational models help identify possibilities, physical experiments test them, and evidence determines which candidates deserve the next step toward becoming a medicine.
